Leveraging Innovation for Precision Medicine

Our Strategy

Our Strategy

Our strategy and business model


Focus on unmet medical needs resulting from specific genetic mutations, drug resistance, or compensatory mechanisms


Build a portfolio of internally discovered and selectively acquired programs structured into asset-based subsidiaries

Fast track

Fast track promising assets from discovery to clinical proof of concept

creative partnerships

Advance programs into pivotal studies and commercialization through creative partnerships


Leverage proven and synergistic capabilities of Jubilant Pharmova's world-class research with in-house development expertise

Therapeutic Index & Brain Exposure Optimization (TIBEO) Discovery Engine


We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.